Momenta Pharmaceuticals, Inc. announced the appointment of Donna Grogan, M.D. to its Board of Directors. Dr. Grogan recently stepped down as the Chief Medical Officer of Clementia Pharmaceuticals (acquired by Ipsen in April 2019) and is a board-certified internal medicine physician with 15 years of experience in clinical medicine. Prior to working at Clementia, Dr. Grogan served as the Chief Medical Officer for several Health Care Venture focused companies including Anexon, Apofore, and DecImmune. She previously worked at FoldRx Pharmaceuticals (acquired by Pfizer October 2010) as Chief Medical Officer. She has been involved with multiple high-profile product approvals including Lunesta, Xopenex HFA, Brovana and most recently the EMA authorization of Vyndaqel (tafamidis) for the treatment of the rare neurologic disease Transthyretin Familial Amyloid Polyneuropathy.